ARS Pharmaceuticals (SPRY) Net Cash Flow (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Net Cash Flow of -$17.0 million for Q1 2026, up 6.82% sequentially from -$18.2 million in Q4 2025, and down 55.17% YoY from -$37.9 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Net Cash Flow (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Net Cash Flow for 7 years, with the latest figure at -$17.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 55.17% year-over-year to -$17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.5 million (up 3.71% YoY) and the FY2025 annual result came in at -$9.5 million, up 52.86% from the prior year.
- Net Cash Flow advanced to -$17.0 million in Q1 2026 per SPRY's latest filing, from -$18.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $173.2 million in Q4 2022 and troughed at -$122.7 million in Q1 2023.
- A 5-year average of -$2.1 million and a median of -$7.6 million in 2022 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 508.91% in 2023, down 1461.7% in 2023.
- Over 5 years, Net Cash Flow stood at $173.2 million in 2022, then tumbled by 93.97% to $10.4 million in 2023, then climbed by 6.91% to $11.2 million in 2024, then sank by 263.44% to -$18.2 million in 2025, then increased by 6.82% to -$17.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$17.0 million, -$18.2 million, and $8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -16.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.16 Mn |
| Jun 30, 2026 | -16.16 Mn |
| Mar 31, 2026 | -17.00 Mn |
| Mar 31, 2026 | -17.00 Mn |
| Dec 31, 2025 | -18.24 Mn |
| Dec 31, 2025 | -18.24 Mn |
| Sep 30, 2025 | 8.02 Mn |
| Sep 30, 2025 | 8.02 Mn |
| Jun 30, 2025 | 11.68 Mn |
| Jun 30, 2025 | 11.68 Mn |
| Mar 31, 2025 | -10.95 Mn |
| Mar 31, 2025 | -10.95 Mn |
| Dec 31, 2024 | 11.16 Mn |
| Dec 31, 2024 | 11.16 Mn |
| Sep 30, 2024 | 3.03 Mn |
| Sep 30, 2024 | 3.03 Mn |
| Jun 30, 2024 | -19.38 Mn |
| Jun 30, 2024 | -19.38 Mn |
| Mar 31, 2024 | -14.97 Mn |
| Mar 31, 2024 | -14.97 Mn |